Bria-Pros / BriaCell - LARVOL DELTA

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ in Breast and Prostate Cancer Models (GlobeNewswire)

Preclinical • Breast Cancer • Prostate Cancer

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ at SITC 2025 (GlobeNewswire) - "Both Bria-BRES+ and Bria-PROS+ produced sustained, and durable anti-cancer immune responses that may translate into prolonged clinical benefit for patients treated with the Bria-OTS+ platform of whole cell immunotherapies."

Preclinical • Breast Cancer • Prostate Cancer

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate Cancer (GlobeNewswire) - "The non-dilutive grant...will be used to complete manufacturing of Bria-PROS+ and to fund the upcoming Phase 1/2a study in patients with advanced prostate cancer."

Financing • Prostate Cancer

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference (GlobeNewswire) - "Both Bria-BRES+ (clinical candidate for breast cancer) and Bria-PROS+ (clinical candidate for prostate cancer) activated key components of the innate immune system, the body’s first line of defense against cancer, including Natural Killer (NK) cells and NKT cells in preclinical cancer models; Activation of the innate immune system by Bria-BRES+ and Bria-PROS+ was mediated by CD86, IL-12, NKG2D and inhibited by HLA class I molecules; Bria-BRES+ and Bria-PROS+ both effectively activated immune cells to destroy breast cancer and prostate cancer cells in a pre-clinical cancer model....The next generation (Bria-OTS+) is expected to enter the clinic in 1H2025 starting with Bria-PROS+ for prostate cancer."

New trial • Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer (GlobeNewswire) - "BriaCell Therapeutics Corp...is pleased to announce that it has received positive feedback from its Pre-IND meeting with the U.S. Food and Drug Administration (FDA), which is a step forward to opening an IND to conduct a Phase 1/2 study of its personalized off-the-shelf immunotherapy, Bria-PROS+, in advanced prostate cancer....As a result of the Pre-IND meeting, FDA waived the animal toxicology and animal pharmacokinetic (PK) studies requirement for opening the IND, greatly simplifying the development pathway for Bria-PROS+™. Other areas of discussion included BriaCell’s plan to initiate the Phase 1/2 study pending completion of standard manufacturing and testing requirements."

FDA event • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS and Bria-PROS Clinical Candidates for Breast and Prostate Cancer (GlobeNewswire) - "BriaCell Therapeutics Corp....is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-OTS and Bria-PROS, in a poster session during the 2024 American Association for Cancer Research (AACR) Annual Meeting held from April 5-10 at San Diego Convention Center, San Diego, CA....BriaCell expects to use Bria-OTS and Bria-PROS in its upcoming phase 1/2a clinical studies for breast and prostate cancer, respectively....Bria-OTS and Bria-PROS engage multiple facets of the adaptive immune response. This may result in lasting anti-cancer effects in patients; Specifically activates Natural Killer (NK) cells to counter cancer immune escape caused by the loss of human leukocyte antigens (HLA)."

Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies (GlobeNewswire) - "BriaCell Therapeutics Corp...announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively....'We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.'"

Licensing / partnership • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing (GlobeNewswire) - "BriaCell Therapeutics Corp...is pleased to announce the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. GMP manufacturing of Bria-Pros+ will provide clinical supplies for planned clinical trial use....'We eagerly anticipate completing Investigational New Drug (IND)-enabling studies during 2024 with Bria-Pros+.'"

Commercial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND (GlobeNewswire) - "Therapeutics Corp...is pleased to report unprecedented activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies at the 2023 Society for Immunotherapy of Cancer (SITC) annual meeting. These novel immunotherapies have been shown to activate the immune system through multiple mechanisms including adaptive responses of naïve (resting) T cells and innate responses of dendritic cells and natural killer (NK) cells leading to enhanced clinical efficacy and prevention of immune escape....In separate news, FDA has stated that BriaCell may proceed with the clinical study of Bria-OTS^™. This opens the path to the clinic for Bria-OTS^™, the first generation of BriaCell’s personalized off-the-shelf cellular immunotherapy for breast cancer."

IND • Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer